Selenium compounds prevent the induction of drug resistance by cisplatin in human ovarian tumor xenografts in vivo

Cancer Chemotherapy and Pharmacology

Volumn 46, Issue 1, 2000, Pages 74-78

  Caffrey, Paula B ^a   Frenkel, Gerald D ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Cisplatin; Drug resistance; Ovarian tumors; Selenium compounds

Indexed keywords

CISPLATIN; GLUTATHIONE; METHIONINE; SELENITE; SELENIUM DERIVATIVE; SELENOMETHIONINE; SULFITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY TUMOR; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR CELL CULTURE; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 0033934636     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000127     Document Type: Article

References (33)

1. 1. Andrews PA, Murphy MP, Howell SB (1989) Characterization of cisplatin resistance in COLO316 human ovarian carcinoma cells. Eur J Cancer Clin Oncol 25: 619-625
2. 2. Ayash LJ, Herman TS, Frei E (1993) Cancer chemotherapy: clinical evidence for drug resistance. In: Teicher B (ed) Drug resistance and oncology. Marcel Dekker, New York, pp 617-635
3. 3. Bailey HH, Gipp JJ, Ripple M, Wilding G, Mulcahy RT (1992) Increase in γ-glutamylcysteine synthetase activity and steady state messenger RNA levels in melphalan-resistant DU145 human prostate carcinoma cells expressing elevated glutathione levels. Cancer Res 52: 5115-5118
4. 4. Baldew GS, Van-den Hamer CJ, Vermeulen NPE, Goeiji JJM de, Mevie JG (1989) Selenium-induced protection against cis-diaminedichloroplatinum (II) nephrotoxicity in mice and rats. Cancer Res 49: 3020-3023
5. 5. Berry JP, Pauwells C, Tlouzeau S, Lespinats G (1984) Effect of selenium in combination with cis-diamminedichloroplati-num(II) in the treatment of murine fibrosarcoma. Cancer Res 44: 2864-2868
6. 6. Caffrey PB, Frenkel GD (1991) Inhibition of cell colony formation by selenite: involvement of glutathione. Mol Pharmacol 39: 281-284
7. 7. Caffrey PB, Frenkel GD (1994) The development of drug resistance by tumor cells in vitro is accompanied by the development of sensitivity to selenite. Cancer Lett 81: 59-65
8. 8. Caffrey PB, Frenkel GD (1998) Treatment of human ovarian tumor xenografts with selenite prevents the melphalan-induced development of drug resistance. Anticancer Res 18: 3017-3020
9. 9. Caffrey PB, Zhang Y, Frenkel GD (1998) Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in vivo. Anticancer Res 18: 3021-3026
10. 10. Caffrey PB, Zhu M, Frenkel GD (1998) Prevention of the development of melphalan resistance in vitro by selenite. Biol Trace Elem Res 65: 187-196
11. 11. Caffrey PB, Zhu M, Zhang Y, Chinen N, Frenkel GD (1999) Rapid development of glutathione S-transferase-dependent drug resistance in vitro and its prevention by ethacrynic acid. Cancer Lett 136: 47-52
12. 12. Chen G, Hutter K-J, Zeller WJ (1995) Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells. Cell Biol Toxicol 11: 273-281
13. 13. Clark LC, Combs GF, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL, Park HK, Sanders BB, Smith CL, Taylor JR (1996) Effects of Se supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. JAMA 276: 1957-1963
14. 14. Combs GF Jr, Combs SB (1986) The role of selenium in nutrition. Academic Press, San Diego, pp 413-461
15. 15. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89: 3070-3074
16. 16. Gosland M, Lum B, Schimmelpfennig J, Baker J, Doukas M (1996) Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Pharmacotherapy 16: 16-39
17. 17. Griffith OW (1982) Mechanism of action, metabolism and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. J Biol Chem 257: 704-713
18. 18. Hamilton TC, Winker MA, Louie KG, Batist G, Behrens BC, Tsuruo T, Grotinger KR, Mckoy WM, Young RC, Ozols RF (1985) Augmentation of Adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 34: 2583-2586
19. 19. Hissin P, Hilf RA (1976) A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 74: 214-226
20. 20. Hu Y, Chen Y, Zhang Y, Zhou M, Song X, Zhang B, Luo L, Xu P, Zhao Y, Cheng G (1997) The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Biol Trace Elem Res 56: 331-341
21. 21. Ip C (1998) Lessons from basic research in selenium and cancer prevention. J Nutr 128: 1845-1854
22. 22. Ishida H, Kijima H, Ohta Y, Kasani-Sabat M, Scanlon K (1995) Mechanisms of cisplatin resistance and its reversal in human tumors. In: Kellen J (ed) Alternative mechanisms of multidrug resistance in cancer. Birkhauser Press, Boston, pp 225-264
23. 23. Kelland L (1997) Platinum complexes. In: Teicher B (ed) Cancer therapeutics: experimental and clinical agents. Humana, Totowa, pp 93-112
24. 24. Lee BJ, Park SI, Park JM, Chittum HS, Hatfield DL (1996) Molecular biology of selenium and its role in human health. Mol Cells 6: 509-520
25. 25. Lee F, Vessey A Rofstad E, Siemann DW, Sutherland R (1989) Heterogeneity of glutathione content in ovarian cancer. Cancer Res 49: 5244-5248
26. 26. Meister A (1989) Metabolism and function of glutathione. In: Dolphin D, Poulson R, Avramovic O (eds) Coenzymes and cofactors. Glutathione: chemical, biochemical and medical aspects. Wiley, New York, pp 367-374
27. 27. Mistry P, Kelland LR, Abel G, Sidhar S, Harrap KR (1991) The relationships between glutathione, glutathione S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 64: 215-220
28. 28. Mulcahy RT, Bailey HH, Gipp JJ (1994) Up-regulation of γ-glutamylcysteine synthetase activity in melphalan-resistant human multiple myeloma cells expressing elevated glutathione levels. Cancer Chemother Pharmacol 34: 67-71
29. 29. Naganuma A, Satoh M, Yokoyama M, Imura N (1983) Selenium efficiently depressed toxic side effect of cis-diamminedichloroplatinum. Res Commun Chem Pathol Pharmacol 42: 127-134
30. 30. Naganuma A, Satoh M, Imura N (1984) Effect of selenite on renal toxicity and antitumor activity of cis-diamminedichloroplatinum in mice inoculated with Ehrlich ascites tumor cell. J Pharm Dyn 7: 217-220
31. 31. Ohkawa K, Tsukada Y, Dohzono H, Koike K, Terashima Y (1988) Effects of co-administration of selenium and cisplatin (CDDP) on CDDP-induced toxicity and antitumor activity. Br J Cancer 58: 38-41
32. 32. Ozols R, Young R (1984) Chemotherapy of ovarian cancer. Semin Oncol 11: 215-263
33. 33. Tew KD, Houghton PJ, Houghton JA (1993) Preclinical and clinical modulation of anticancer drugs. CRC Press, Boca Raton, pp 1-12